The Biology of LIF During Pneumonia
肺炎期间 LIF 的生物学
基本信息
- 批准号:9066165
- 负责人:
- 金额:$ 40.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-15 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcute Lung InjuryAcute-Phase ProteinsAddressAlveolarApoptosisBacterial PneumoniaBiologicalBiological AssayBiologyBloodCellsCessation of lifeClinicalCommunitiesDataDiseaseDissectionEngineeringEpithelialEpithelial CellsEquilibriumExtravasationFamilyFutureGenesGoalsHomeostasisHost DefenseImmune responseImmunityIn VitroInfectionInflammationInflammatoryInjuryInterleukin-6InterventionKnowledgeLIF geneLaboratoriesLeukocytesLiquid substanceLiverLower Respiratory Tract InfectionLungMeasuresMediatingMicrobeMolecularMolecular TargetMucous MembraneMusNatural ImmunityPathway interactionsPatientsPhenotypePhysiologicalPlasmaPneumoniaPopulationPreventionProcessProductionPublic HealthRecombinantsRecruitment ActivityRegulationRiskSTAT3 geneSerumSignal TransductionSiteSourceSystemTestingTissuesVariantantimicrobialbaseburden of illnesscell typecytokinegenetic approachin vivoindexinginnovationinsightleukemia inhibitory factor receptorlung injuryneutrophilnovelresearch studyresponsetranscription factor
项目摘要
DESCRIPTION (provided by applicant): Lung infections account for a tremendous burden of disease worldwide, representing the most frequent cause of infection-related deaths and a leading cause of acute lung injury. Overcoming lower respiratory tract infection requires a critica yet dangerous innate immune response, typified by robust inflammation. The biological signals eliciting innate immunity must be delicately balanced by mechanisms maintaining tissue integrity and homeostasis. How these pathways converge to promote adequate host defense while limiting inflammatory injury is poorly understood. We have recently shown that during bacterial pneumonia, the cytokine leukemia inhibitory factor (LIF) is critical for activation of the transcription factor STAT3, which has emerged as an important signaling hub for both antimicrobial defense and tissue protection in the lungs and other mucosal tissue sites. However, the regulation and functional significance of LIF during lung infection is virtually unknown. Preliminary results indicate that LIF neutralization causes a profound increase in lung injury in pneumonic mice, suggesting that LIF serves to offset inflammatory injury in response to infectious microbes. By pursuing the following aims, we will test the central hypothesis that LIF is a critical determinant of tissue protection during pneumonia: Aim 1) Test the hypothesis that LIF is necessary and sufficient for STAT3- mediated protection against lung injury during pneumonia; Aim 2) Test the hypothesis that during pneumonia neutrophils elaborate LIF in a RelA-dependent manner to counter inflammatory lung injury; and Aim 3) Test the hypothesis that the soluble variant of the LIF receptor is a negative acute phase protein regulating LIF biological activity during pneumonia. By elucidating the biology of this understudied and poorly understood pathway, pursuit of these aims will provide novel insights regarding the cellular and molecular mechanisms of tissue protection during pneumonia. Moreover, dissection of the LIF-STAT3 pathway during lung infection has clear potential for future translational directions, as it is anticipated to reveal candidate molecular targets for better identifying and/or treating patient with or at risk for acute lung injury.
描述(由申请人提供):肺部感染是全球范围内的巨大疾病负担,是感染相关死亡的最常见原因,也是急性肺损伤的主要原因。克服下呼吸道感染需要一个关键但危险的先天免疫反应,典型的是强烈的炎症。引发先天免疫的生物信号必须通过维持组织完整性和体内平衡的机制来微妙地平衡。这些途径如何汇聚以促进足够的宿主防御,同时限制炎症损伤还知之甚少。我们最近发现,在细菌性肺炎期间,细胞因子白血病抑制因子(LIF)对于转录因子STAT 3的激活至关重要,STAT 3已成为肺和其他粘膜组织部位抗菌防御和组织保护的重要信号枢纽。然而,LIF在肺部感染过程中的调节和功能意义几乎是未知的。初步结果表明,LIF中和导致肺炎小鼠肺损伤的显著增加,表明LIF用于抵消响应于感染性微生物的炎性损伤。通过追求以下目标,我们将检验中心假设,即LIF是肺炎期间组织保护的关键决定因素:目的1)检验LIF对于肺炎期间STAT 3介导的肺损伤保护是必要和充分的假设;目的2)检验肺炎期间中性粒细胞以RelA依赖性方式阐述LIF以对抗炎性肺损伤的假设;和目的3)检验LIF受体的可溶性变体是在肺炎期间调节LIF生物活性的负急性期蛋白的假设。通过阐明这一研究不足和了解甚少的途径的生物学,追求这些目标将提供有关肺炎期间组织保护的细胞和分子机制的新见解。此外,在肺部感染期间对LIF-STAT 3通路的解剖对于未来的翻译方向具有明确的潜力,因为预计它将揭示候选分子靶标,用于更好地鉴定和/或治疗患有急性肺损伤或有急性肺损伤风险的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lee Quinton其他文献
Lee Quinton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lee Quinton', 18)}}的其他基金
LOX-1 as a protective countermeasure in response to lung infection
LOX-1 作为应对肺部感染的保护性对策
- 批准号:
10677924 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
LOX-1 as a protective countermeasure in response to lung infection
LOX-1 作为应对肺部感染的保护性对策
- 批准号:
10690260 - 财政年份:2022
- 资助金额:
$ 40.93万 - 项目类别:
Liver-derived protection during pneumonia and sepsis
肺炎和败血症期间的肝源性保护
- 批准号:
9309668 - 财政年份:2017
- 资助金额:
$ 40.93万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
Identification of novel phenotypes of acute lung injury using multimodal longitudinal data
使用多模态纵向数据识别急性肺损伤的新表型
- 批准号:
MR/Y000404/1 - 财政年份:2023
- 资助金额:
$ 40.93万 - 项目类别:
Fellowship